Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors

American Journal of Human Genetics

Volumn 98, Issue 5, 2016, Pages 818-829

  Decker, Brennan ^a,b   Karyadi, Danielle M ^a   Davis, Brian W ^a   Karlins, Eric ^a   Tillmans, Lori S ^c   Stanford, Janet L ^d   Thibodeau, Stephen N ^c   Ostrander, Elaine A ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MAYO CLINIC   (United States)

^d USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TRANSCRIPTION FACTOR DP1; BRCA2 PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ALLELIC IMBALANCE; ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CELL INTERACTION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; FOCAL ADHESION; GENE DELETION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GENOTYPING TECHNIQUE; GERMLINE MUTATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; INDEL MUTATION; MALE; MISMATCH REPAIR; MUTAGENESIS; MUTATION RATE; PRIORITY JOURNAL; PROSTATE CANCER; SOMATIC MUTATION; GENETICS; HIGH THROUGHPUT SEQUENCING; LYMPH NODE METASTASIS; MIDDLE AGED; MUTATION; PROCEDURES; PROGNOSIS; PROSTATE TUMOR; SECONDARY;

AGED; ALLELES; BRCA2 PROTEIN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 84963562984     PISSN: 00029297     EISSN: 15376605     Source Type: Journal    
DOI: 10.1016/j.ajhg.2016.03.003     Document Type: Article

References (52)

1. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA Cancer J. Clin. 65 2015 5 29
2. C.E. DeSantis, C.C. Lin, A.B. Mariotto, R.L. Siegel, K.D. Stein, J.L. Kramer, R. Alteri, A.S. Robbins, and A. Jemal Cancer treatment and survivorship statistics, 2014 CA Cancer J. Clin. 64 2014 252 271
3. C.S. Grasso, Y.-M. Wu, D.R. Robinson, X. Cao, S.M. Dhanasekaran, A.P. Khan, M.J. Quist, X. Jing, R.J. Lonigro, J.C. Brenner, and et al. The mutational landscape of lethal castration-resistant prostate cancer Nature 487 2012 239 243
4. C.E. Barbieri, S.C. Baca, M.S. Lawrence, F. Demichelis, M. Blattner, J.-P. Theurillat, T.A. White, P. Stojanov, E. Van Allen, N. Stransky, and et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer Nat. Genet. 44 2012 685 689
5. S.C. Baca, D. Prandi, M.S. Lawrence, J.M. Mosquera, A. Romanel, Y. Drier, K. Park, N. Kitabayashi, T.Y. MacDonald, M. Ghandi, and et al. Punctuated evolution of prostate cancer genomes Cell 153 2013 666 677
6. A. Kumar, T.A. White, A.P. MacKenzie, N. Clegg, C. Lee, R.F. Dumpit, I. Coleman, S.B. Ng, S.J. Salipante, M.J. Rieder, and et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers Proc. Natl. Acad. Sci. USA 108 2011 17087 17092
7. M.F. Berger, M.S. Lawrence, F. Demichelis, Y. Drier, K. Cibulskis, A.Y. Sivachenko, A. Sboner, R. Esgueva, D. Pflueger, C. Sougnez, and et al. The genomic complexity of primary human prostate cancer Nature 470 2011 214 220
8. D. Robinson, E.M. Van Allen, Y.-M. Wu, N. Schultz, R.J. Lonigro, J.-M. Mosquera, B. Montgomery, M.-E. Taplin, C.C. Pritchard, G. Attard, and et al. Integrative clinical genomics of advanced prostate cancer Cell 161 2015 1215 1228
9. H. Beltran, R. Yelensky, G.M. Frampton, K. Park, S.R. Downing, T.Y. MacDonald, M. Jarosz, D. Lipson, S.T. Tagawa, D.M. Nanus, and et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity Eur. Urol. 63 2013 920 926
10. A. Abeshouse, J. Ahn, R. Akbani, A. Ally, S. Amin, C.D. Andry, M. Annala, A. Aprikian, J. Armenia, A. Arora, et al. Cancer Genome Atlas Research Network The molecular taxonomy of primary prostate cancer Cell 163 2015 1011 1025
11. S. Nik-Zainal, L.B. Alexandrov, D.C. Wedge, P. Van Loo, C.D. Greenman, K. Raine, D. Jones, J. Hinton, J. Marshall, L.A. Stebbings, et al. Breast Cancer Working Group of the International Cancer Genome Consortium Mutational processes molding the genomes of 21 breast cancers Cell 149 2012 979 993
12. L.B. Alexandrov, S. Nik-Zainal, D.C. Wedge, S.A.J.R. Aparicio, S. Behjati, A.V. Biankin, G.R. Bignell, N. Bolli, A. Borg, A.-L. Børresen-Dale, et al. Australian Pancreatic Cancer Genome Initiative ICGC Breast Cancer Consortium ICGC MMML-Seq Consortium ICGC PedBrain Signatures of mutational processes in human cancer Nature 500 2013 415 421
13. D. Yang, S. Khan, Y. Sun, K. Hess, I. Shmulevich, A.K. Sood, and W. Zhang Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer JAMA 306 2011 1557 1565
14. L.B. Alexandrov, S. Nik-Zainal, H.C. Siu, S.Y. Leung, and M.R. Stratton A mutational signature in gastric cancer suggests therapeutic strategies Nat. Commun. 6 2015 8683
15. N. Waddell, M. Pajic, A.-M. Patch, D.K. Chang, K.S. Kassahn, P. Bailey, A.L. Johns, D. Miller, K. Nones, K. Quek, et al. Australian Pancreatic Cancer Genome Initiative Whole genomes redefine the mutational landscape of pancreatic cancer Nature 518 2015 495 501
16. A.-M. Patch, E.L. Christie, D. Etemadmoghadam, D.W. Garsed, J. George, S. Fereday, K. Nones, P. Cowin, K. Alsop, P.J. Bailey, et al. Australian Ovarian Cancer Study Group Whole-genome characterization of chemoresistant ovarian cancer Nature 521 2015 489 494
17. H. Li, and R. Durbin Fast and accurate short read alignment with Burrows-Wheeler transform Bioinformatics 25 2009 1754 1760
18. A. McKenna, M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis, A. Kernytsky, K. Garimella, D. Altshuler, S. Gabriel, M. Daly, and M.A. DePristo The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data Genome Res. 20 2010 1297 1303
19. M.A. DePristo, E. Banks, R. Poplin, K.V. Garimella, J.R. Maguire, C. Hartl, A.A. Philippakis, G. del Angel, M.A. Rivas, M. Hanna, and et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data Nat. Genet. 43 2011 491 498
20. K. Cibulskis, M.S. Lawrence, S.L. Carter, A. Sivachenko, D. Jaffe, C. Sougnez, S. Gabriel, M. Meyerson, E.S. Lander, and G. Getz Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples Nat. Biotechnol. 31 2013 213 219
21. W. McLaren, B. Pritchard, D. Rios, Y. Chen, P. Flicek, and F. Cunningham Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor Bioinformatics 26 2010 2069 2070
22. M. Kircher, D.M. Witten, P. Jain, B.J. O'Roak, G.M. Cooper, and J. Shendure A general framework for estimating the relative pathogenicity of human genetic variants Nat. Genet. 46 2014 310 315
23. J.C. Barrett, B. Fry, J. Maller, and M.J. Daly Haploview: analysis and visualization of LD and haplotype maps Bioinformatics 21 2005 263 265
24. M. Mayrhofer, S. DiLorenzo, and A. Isaksson Patchwork: allele-specific copy number analysis of whole-genome sequenced tumor tissue Genome Biol. 14 2013 R24
25. T. Rausch, T. Zichner, A. Schlattl, A.M. Stütz, V. Benes, and J.O. Korbel DELLY: structural variant discovery by integrated paired-end and split-read analysis Bioinformatics 28 2012 i333 i339
26. R Team R: A Language and Environment for Statistical Computing 2013 R Foundation for Statistical Computing Vienna
27. A. Subramanian, P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A. Paulovich, S.L. Pomeroy, T.R. Golub, E.S. Lander, and J.P. Mesirov Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles Proc. Natl. Acad. Sci. USA 102 2005 15545 15550
28. C. Hunter, R. Smith, D.P. Cahill, P. Stephens, C. Stevens, J. Teague, C. Greenman, S. Edkins, G. Bignell, H. Davies, and et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy Cancer Res. 66 2006 3987 3991
29. J.K. Moore, and J.E. Haber Cell cycle and genetic requirements of two pathways of nonhomologous end-joining repair of double-strand breaks in Saccharomyces cerevisiae Mol. Cell. Biol. 16 1996 2164 2173
30. A. Malkova, and J.E. Haber Mutations arising during repair of chromosome breaks Annu. Rev. Genet. 46 2012 455 473
31. S.A. Narod, S. Neuhausen, G. Vichodez, S. Armel, H.T. Lynch, P. Ghadirian, S. Cummings, O. Olopade, D. Stoppa-Lyonnet, F. Couch, et al. Hereditary Breast Cancer Study Group Rapid progression of prostate cancer in men with a BRCA2 mutation Br. J. Cancer 99 2008 371 374
32. A. Mitra, C. Fisher, C.S. Foster, C. Jameson, Y. Barbachanno, J. Bartlett, E. Bancroft, R. Doherty, Z. Kote-Jarai, S. Peock, et al. IMPACT and EMBRACE Collaborators Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype Br. J. Cancer 98 2008 502 507
33. E. Castro, C. Goh, D. Leongamornlert, E. Saunders, M. Tymrakiewicz, T. Dadaev, K. Govindasami, M. Guy, S. Ellis, D. Frost, and et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer Eur. Urol. 68 2015 186 193
34. Breast Cancer Linkage Consortium Cancer risks in BRCA2 mutation carriers J. Natl. Cancer Inst. 91 1999 1310 1316
35. S.A. Gayther, K.A. de Foy, P. Harrington, P. Pharoah, W.D. Dunsmuir, S.M. Edwards, C. Gillett, A. Ardern-Jones, D.P. Dearnaley, D.F. Easton, et al. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer Cancer Res. 60 2000 4513 4518
36. Z. Kote-Jarai, D. Leongamornlert, E. Saunders, M. Tymrakiewicz, E. Castro, N. Mahmud, M. Guy, S. Edwards, L. O'Brien, E. Sawyer, et al. UKGPCS Collaborators BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients Br. J. Cancer 105 2011 1230 1234
37. I. Agalliu, E. Karlins, E.M. Kwon, L.M. Iwasaki, A. Diamond, E.A. Ostrander, and J.L. Stanford Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer Br. J. Cancer 97 2007 826 831
38. C.S. Sinclair, R. Berry, D. Schaid, S.N. Thibodeau, and F.J. Couch BRCA1 and BRCA2 have a limited role in familial prostate cancer Cancer Res. 60 2000 1371 1375
39. G. Attard, C. Parker, R.A. Eeles, F. Schröder, S.A. Tomlins, I. Tannock, C.G. Drake, and J.S. de Bono Prostate cancer Lancet 387 2016 70 82
40. E.K. Bancroft, E.C. Page, E. Castro, H. Lilja, A. Vickers, D. Sjoberg, M. Assel, C.S. Foster, G. Mitchell, K. Drew, et al. IMPACT Collaborators Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study Eur. Urol. 66 2014 489 499
41. F. Xia, D.G. Taghian, J.S. DeFrank, Z.C. Zeng, H. Willers, G. Iliakis, and S.N. Powell Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining Proc. Natl. Acad. Sci. USA 98 2001 8644 8649
42. V.P. Yu, M. Koehler, C. Steinlein, M. Schmid, L.A. Hanakahi, A.J. van Gool, S.C. West, and A.R. Venkitaraman Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation Genes Dev. 14 2000 1400 1406
43. L. Zheng, S. Li, T.G. Boyer, and W.H. Lee Lessons learned from BRCA1 and BRCA2 Oncogene 19 2000 6159 6175
44. A. Tutt, A. Gabriel, D. Bertwistle, F. Connor, H. Paterson, J. Peacock, G. Ross, and A. Ashworth Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification Curr. Biol. 9 1999 1107 1110
45. J.Z. Press, A. De Luca, N. Boyd, S. Young, A. Troussard, Y. Ridge, P. Kaurah, S.E. Kalloger, K.A. Blood, M. Smith, and et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities BMC Cancer 8 2008 17
46. L.H. Saal, S.K. Gruvberger-Saal, C. Persson, K. Lövgren, M. Jumppanen, J. Staaf, G. Jönsson, M.M. Pires, M. Maurer, K. Holm, and et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair Nat. Genet. 40 2008 102 107
47. F.C. Martins, S. De, V. Almendro, M. Gönen, S.Y. Park, J.L. Blum, W. Herlihy, G. Ethington, S.J. Schnitt, N. Tung, and et al. Evolutionary pathways in BRCA1-associated breast tumors Cancer Discov. 2 2012 503 511
48. B.S. Carver, J. Tran, A. Gopalan, Z. Chen, S. Shaikh, A. Carracedo, A. Alimonti, C. Nardella, S. Varmeh, P.T. Scardino, and et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate Nat. Genet. 41 2009 619 624
49. A. Hübner, D.J. Mulholland, C.L. Standen, M. Karasarides, J. Cavanagh-Kyros, T. Barrett, H. Chi, D.L. Greiner, C. Tournier, C.L. Sawyers, and et al. JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate Proc. Natl. Acad. Sci. USA 109 2012 12046 12051
50. J. Jonkers, R. Meuwissen, H. van der Gulden, H. Peterse, M. van der Valk, and A. Berns Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer Nat. Genet. 29 2001 418 425
51. J. Mateo, S. Carreira, S. Sandhu, S. Miranda, H. Mossop, R. Perez-Lopez, D. Nava Rodrigues, D. Robinson, A. Omlin, N. Tunariu, and et al. DNA-repair defects and olaparib in metastatic prostate cancer N. Engl. J. Med. 373 2015 1697 1708
52. C.C. Pritchard, C. Morrissey, A. Kumar, X. Zhang, C. Smith, I. Coleman, S.J. Salipante, J. Milbank, M. Yu, W.M. Grady, and et al. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer Nat. Commun. 5 2014 4988